Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Net Cash Flow for 8 consecutive years, with -$71.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow changed 0.44% year-over-year to -$71.9 million, compared with a TTM value of -$241.8 million through Sep 2025, down 176.42%, and an annual FY2024 reading of $353.8 million, up 89.73% over the prior year.
  • Net Cash Flow was -$71.9 million for Q3 2025 at Bicycle Therapeutics, up from -$73.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $504.6 million in Q2 2024 and bottomed at -$87.0 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $27.0 million, with a median of -$25.9 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 1200.46% in 2022, then soared 2780.59% in 2023.
  • Year by year, Net Cash Flow stood at $179.2 million in 2021, then crashed by 114.44% to -$25.9 million in 2022, then crashed by 81.5% to -$47.0 million in 2023, then skyrocketed by 79.64% to -$9.6 million in 2024, then plummeted by 651.77% to -$71.9 million in 2025.
  • Business Quant data shows Net Cash Flow for BCYC at -$71.9 million in Q3 2025, -$73.3 million in Q2 2025, and -$87.0 million in Q1 2025.